We are live on ! Find out more
MTIM

Marathon Trading Investment Management Portfolio holdings

AUM $3.23B
1-Year Est. Return 31.02%
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+31.02%
3 Year Est. Return
+143.44%
5 Year Est. Return
+98.73%
10 Year Est. Return
+717.06%
AUM
$1.11B
AUM Growth
-$213M
Cap. Flow
-$240M
Cap. Flow %
-21.63%
Top 10 Hldgs %
49.49%
Holding
359
New
67
Increased
68
Reduced
110
Closed
87

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$78.5M
2
AAPL icon
Apple
AAPL
+$44.2M
3
PDD icon
Pinduoduo
PDD
+$13.1M
4
C icon
Citigroup
C
+$11.2M
5
GLD icon
SPDR Gold Trust
GLD
+$8.1M

Sector Composition

Rank Sector Weight
1 Financials 8.3%
2 Technology 2.57%
3 Consumer Discretionary 2.04%
4 Communication Services 0.99%
5 Consumer Staples 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AMGN icon
276
Amgen
AMGN
$225B
-1,500
Closed -$469K
APLT
277
DELISTED
Applied Therapeutics
APLT
-15,907
Closed -$74.3K
AQST icon
278
Aquestive Therapeutics
AQST
$531M
-18,225
Closed -$47.4K
BDTX icon
279
Black Diamond Therapeutics
BDTX
$121M
-19,116
Closed -$89.1K
BIDU icon
280
Baidu
BIDU
$35.6B
-1,417
Closed -$123K
BIDU icon
281
PUT
Baidu
BIDU
$35.6B
-1,500
Closed -$130K
BLND icon
282
Blend Labs
BLND
$331M
-35,572
Closed -$84K
BVS icon
283
Bioventus
BVS
$1.17B
-18,841
Closed -$108K
CCCC icon
284
C4 Therapeutics
CCCC
$480M
-14,400
Closed -$66.5K
CHWY icon
285
CALL
Chewy
CHWY
$9.15B
-18,500
Closed -$504K
CHWY icon
286
Chewy
CHWY
$9.15B
-39,500
Closed -$1.08M
CHWY icon
287
PUT
Chewy
CHWY
$9.15B
-400
Closed -$10.9K
CRDF icon
288
Cardiff Oncology
CRDF
$77.1M
-17,580
Closed -$39K
CSL icon
289
Carlisle Companies
CSL
$15.2B
-562
Closed -$228K
ELEV
290
DELISTED
Elevation Oncology
ELEV
-13,705
Closed -$37K
EOLS icon
291
CALL
Evolus
EOLS
$536M
-25,000
Closed -$271K
ESPR
292
DELISTED
Esperion Therapeutics
ESPR
-31,070
Closed -$69K
F icon
293
PUT
Ford
F
$55.1B
-10,000
Closed -$125K
FSP
294
Franklin Street Properties
FSP
$46.3M
-40,060
Closed -$61.3K
FULC icon
295
Fulcrum Therapeutics
FULC
$284M
-10,800
Closed -$67K
FXI icon
296
iShares China Large-Cap ETF
FXI
$4.2B
-175,089
Closed -$4.55M
FXY icon
297
Invesco CurrencyShares Japanese Yen Trust
FXY
$426M
-7,500
Closed -$431K
GIS icon
298
General Mills
GIS
$20.4B
-4,000
Closed -$253K
GM icon
299
PUT
General Motors
GM
$76.1B
-30,000
Closed -$1.39M
HE icon
300
Hawaiian Electric Industries
HE
$2.06B
-12,100
Closed -$109K

Similar funds

Marathon Trading Investment Management's Q3 2024 Portfolio in Review

As of Q3 2024, Marathon Trading Investment Management held 359 positions worth $1.11B, down 16% from $1.32B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Marathon Trading Investment Management withdrew a net $240M in Q3 2024, closing 87 positions and reducing 110 holdings. Its most notable exit was iShares China Large-Cap ETF, an estimated $4.55M position sold in full.

By sector, the portfolio is most concentrated in Financials at 8.3% of assets, up from 7.3% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Marathon Trading Investment Management opened a new position in Invesco QQQ Trust worth $3.03M.

  • Marathon Trading Investment Management's largest Q3 2024 buy was Invesco QQQ Trust: 6,214 shares worth $3.03M.
  • Marathon Trading Investment Management added most to Strategy Inc in Q3 2024, an estimated $10.5M increase.
  • Marathon Trading Investment Management's biggest Q3 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $78.5M.
  • Marathon Trading Investment Management fully exited iShares China Large-Cap ETF in Q3 2024, selling an estimated $4.55M.
  • Marathon Trading Investment Management's ten largest holdings make up 49% of its $1.11B portfolio in Q3 2024.
  • Marathon Trading Investment Management opened 67 new positions and closed 87 in Q3 2024.
  • Marathon Trading Investment Management's portfolio value fell 16% quarter-over-quarter to $1.11B.

Based on Marathon Trading Investment Management's 13F filing for Q3 2024, filed 7 Nov 2024.